spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Max Planck researchers feed Proteome AI with PharmaFluidics technology

PharmaFluidics

Micro-chip based µPAC LC columns - key component in NATURE study doubling the universe of known proteins across all kingdoms of life.




Ghent, Belgium – June 18, 2020
 
PharmaFluidics NV, innovative player in the field of analytical chromatography, is excited to announce that researchers of Prof. Matthias Mann’s Group at the Max Planck Institute in Munich have integrated its unique high-resolution µPAC™ micro-Chip technology in their advanced proteomics workflow.
 
In their newly published Nature study, they report the in-depth protein profiling of 100 taxonomically diverse organisms. With more than 340.000 protein identifications obtained in a standardized manner, their study doubles the number of evidenced proteins known to the scientific community hitherto.
 
The data set also provides an important and large-scale use case for sequence-based deep learning algorithms, as demonstrated by experimentally confirming predicted peptide properties of Bacteroides uniformis. The study was published as “The Proteome Landscape of the Kingdoms of Life” in the June edition of NATURE, a leading, high impact science journal.
 
“The microstructured and extremely reproducible µPAC™ chromatographic system is conducive to the generation of high quality, standardized data sets across time and lab sites, which are key for optimal  performance of our proteome machine learning algorithm; this is also of high importance for future clinical and diagnostics purposes” Philipp Geyer and Johannes Mueller, researchers at the MPI commented.
 
“We are grateful to MPI for bringing PharmaFluidics’ technology to the forefront of protein biology, and to our own staff for relentless support to their fellow-scientists”, added Johan Devenyns, CEO.
 
About PharmaFluidics

PharmaFluidics develops and commercializes its unique μPACᵀᴹ range of micro-chip based chromatography columns for use in biomarker, diagnostics and drug research & development applications in the global biotech and pharma industries. The unprecedented, game-changing separation performance of PharmaFluidics’ μPACᵀᴹ chromatography columns allows to identify substantially more compounds in complex biological samples, such as biopsies, proteome digests, culture media or bio-pharmaceutical actives.

The key expertise and IP estate of PharmaFluidics are the design, lithographic production, and surface treatment of silicon wafers for use as separation devices in liquid chromatography. PharmaFluidics collaborates with an extensive network of centers of excellence and pioneer users to develop an increasing range of applications.

phone +32 (0)9 241 56 57
web https://www.pharmafluidics.com/
email Technologiepark-Zwijnaarde 82 B-9052 Ghent (Zwijnaarde) BELGIUM
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Business Continuity Plan - Message from Protagen Protein Services (PPS)

Following the recent COVID-19 outbreak, we at Protagen Protein Services (PPS) are preparing for all eventualities. Please be assured that PPS will continue to operate as normal providing you with all of the professional support and service you have to come to expect from us. Given the gravity of the situation, and to protect our staff, clients, and communities from the spread of the virus, we have taken various measures within a scope of a Business Continuity Plan:
More info >>


White Papers

Convergence in the Pharmaceutical Market

PCI Pharma Services

Convergence is currently playing a large part in the growth of the pharmaceutical market. The need for convergence is due to many factors including the declining economy and high competition within the sector. There are many convergences within this sector to date; these include the convergence of food based products with medical and health products and the convergence of prescription drugs to over the counter (OTC) products. Although convergence is helping the pharmaceutical industry expand and develop, it also poses some challenges; these include the regulatory outlook and counterfeiting.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement